Filing Flows

Filing Flows › Companies › Staar Surgical › Cash flow

Staar Surgical cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$26.4M in Q3 2026 · $17.8M over twelve months

Operating cash flow$27.3M
Capital spending−$935K
Free cash flow+$26.4M
Cash / net income4.9×
Cash conversion cycle49 days

Analysis

In Q3 2026, Staar Surgical generated $27.3M of operating cash flow and spent $935K on capital projects, leaving free cash flow of $26.4M.

Over the twelve months to Oct 2, 2026, operating cash flow was $21.4M; the largest uses were other investing ($55.8M), taxes on employees’ shares ($6.1M), capital spending ($3.5M); besides operations, cash came from shares issued ($1.5M), other financing ($9K); the cash balance fell by $42.5M.

Operating cash flow was $27.3M against net income of $5.6M — 4.9× profit, cash ran ahead of reported earnings. The largest differences: receivables +$12.1M, other liabilities +$5.8M, stock-based pay +$5.5M.

Its cash conversion cycle was 49 days (receivables 101 + inventory 0 − payables 52).

Free cash flow

Staar Surgical: free cash flow by quarterStaar Surgical: free cash flow by quarter−$5.1MQ4 2024−$7.2MQ1 2025−$29.0MQ2 2025$1.8MQ3 2025−$5.6MQ4 2025−$22.1MQ1 2026$19.2MQ2 2026$26.4MQ3 2026
Operating cash flow less capital spending.
Staar Surgical: operating cash flow against capital spendingStaar Surgical: operating cash flow against capital spendingOperating cash flowCapital spending$642K$5.7MQ4 2024−$5.7M$1.5MQ1 2025−$27.2M$1.8MQ2 2025$2.7M$883KQ3 2025−$3.9M$1.7MQ4 2025−$21.7M$443KQ1 2026$19.7M$494KQ2 2026$27.3M$935KQ3 2026
Latest (Q3 2026): Operating cash flow $27.3M, Capital spending $935K.

Capital allocation, year by year

Staar Surgical: where the cash came from (up) and went (down), by fiscal yearStaar Surgical: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow $44.0MFY2021: Net borrowing −$1.6MFY2021: Shares issued $19.4MFY2021: Capital spending −$13.6M$63.4MFY2021FY2022: Operating cash flow $35.7MFY2022: Net borrowing −$126KFY2022: Shares issued $8.4MFY2022: Capital spending −$18.1M$44.1MFY2022FY2023: Operating cash flow $14.6MFY2023: Net borrowing −$161KFY2023: Shares issued $9.7MFY2023: Capital spending −$18.2M$24.3MFY2023FY2024: Operating cash flow $15.7MFY2024: Net borrowing −$165KFY2024: Shares issued $7.4MFY2024: Capital spending −$23.4M$23.1MFY2024FY2025: Operating cash flow −$34.2MFY2025: Net borrowing −$42KFY2025: Shares issued $3.5MFY2025: Capital spending −$5.8MFY2025: Buybacks −$6.5M$3.5MFY2025
Over these 5 years operating cash flow totalled $75.8M; the largest uses were capital spending ($79.2M) and operating cash flow ($34.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$206M
Debtnone
Net cash$206M

Staar Surgical funds itself: free cash flow was $17.8M over the last twelve months, with $206M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Staar Surgical: sources (+) and uses (−) of cash, Q3 2026Staar Surgical: sources (+) and uses (−) of cash, Q3 2026Other investing−$39.7MOperating cash flow$27.3MCash drawn (+) / kept (−)$15.0MTaxes on employees’ shares−$1.3MCapital spending−$935KExchange rates−$297KShares issued$3KOther financing$1K
Staar Surgical: sources (+) and uses (−) of cash, TTM to Q3 2026Staar Surgical: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$55.8MCash drawn (+) / kept (−)$42.5MOperating cash flow$21.4MTaxes on employees’ shares−$6.1MCapital spending−$3.5MShares issued$1.5MExchange rates−$75KOther financing$9K

From profit to cash

Staar Surgical: net income to operating cash flow, Q3 2026Staar Surgical: net income to operating cash flow, Q3 2026Net income$5.6MDepreciation & amortization$2.4MStock-based pay$5.5MDeferred taxes−$700KReceivables$12.1MInventory−$586KPayables$677KOther liabilities$5.8MOperating cash flow$27.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 2026101—5249
Q2 202687—4245
Q1 202664—3726
Q4 202593—7221
Q3 202545—58-13
Q2 202576—94-18
Q1 2025126—8838
Q4 2024170—8387

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$27.3M−$935K——$3K$15.0M$26.4M
Q2 2026$19.7M−$494K——$1.2M−$16.7M$19.2M
Q1 2026−$21.7M−$443K——$170K$21.3M−$22.1M
Q4 2025−$3.9M−$1.7M——$114K$23.0M−$5.6M
Q3 2025$2.7M−$883K−$2.0M—$3.0M−$9.0M$1.8M
Q2 2025−$27.2M−$1.8M——$11K$6.0M−$29.0M
Q1 2025−$5.7M−$1.5M—−$42K$376K−$29.0M−$7.2M
Q4 2024$642K−$5.7M—−$41K$40K$19.8M−$5.1M

Staar Surgical: income statement and cash flow

Staar Surgical, Q3 2026: revenue $83.4M (-12% year over year), operating margin 6.5%. The chart follows the revenue to costs, profit and cash.

Staar Surgical: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.